Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration

A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With Neovascular Age-related Macular Degeneration Multicenter Anti VEGF Trial in Austria (MANTA)

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00710229

Acronym

MANTA

Enrollment

320

Registered

2008-07-04

Start date

2008-07-31

Completion date

Unknown

Last updated

2010-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration

Keywords

age related macular degeneration, Ranibizumab-Lucentis, Bevacizumab-Avastin

Brief summary

Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic processes in the eye. This forms the basis for new therapeutic interventions in exudative AMD. Currently two drugs have been approved by the FDA and one drug is used off-label. All these drugs are administered intravitreally. The present study aims to directly compare the effects ranibizumab and bevacizumab in a randomized controlled study in patients with neovascular AMD.

Interventions

DRUGRanibizumab

intravitreal injection

DRUGBevacizumab

intravitreal injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 50 years * Active primary or recurrent subfoveal lesion with CNV secondary to AMD

Exclusion criteria

Prior treatment with any intravitreal drug in the study eye * Prior treatment with verteporfin photodynamic therapy in the study eye * Prior treatment with systemic bevacizumab * Prior treatment with any intravitreal durg or verteprofin photodynamic therapy in the nonstudy eye within the 3 moths before the study entry * Laser photocoagulation within 1 month before study entry in the study eye * Previous participation in any clinical trial within 1 month before the entry of the study * Subfoveal fibrosis or atrophy in the study eye * CNV in either of the two eye due to causes other than AMD such as histoplasmosis or pathologica myopia * Retinal pigment epithelial tear involving the macula in the study eye * Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the 12 month study period or that could contribute to a loss of best corrected visual acuity over the 12 months study period (e.g. diabetic retinopathy, cataract, uncontrolled glaucoma). The decision on exclusion is to be based on the opinion of the local principal investigator. * Active intraocular inflammation * Vitreous hemorrhage in the study eye

Design outcomes

Primary

Measure	Time frame
Change of visual acuity over time	12 months

Secondary

Measure	Time frame
Adverse events retinal thickness (OCT)	12 months

Countries

Austria

Contacts

Primary ContactIlse Krebs, MD

Ilse.Krebs@wienkav.at43-17-1165

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026